The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways

Current Opinion in Structural Biology

Volumn 8, Issue 1, 1998, Pages 101-106

  Kelly, Jeffery W ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; HEMOGLOBIN; HEMOGLOBIN S; LYSOZYME; PREALBUMIN; PROTEIN;

AMYLOID NEUROPATHY; CONFORMATIONAL TRANSITION; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; REVIEW;

EID: 0032006678     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-440X(98)80016-X     Document Type: Article

References (60)

1. Jacobson DR, Buxbaum JN. Genetic aspects of amyloidosis. Adv Hum Genet. 20:1991;69-123.
2. Sipe JD. Amyloidosis. Ann Rev Biochem. 61:1992;947-975.
3. Pepys MB. Amyloidosis. Samter M. Immunological Diseases. 1998;631-674 Little, Brown and Company, Boston.
4. Sipe JD. Amyloidosis. Crit Rev Clin Lab Sci. 31:1994;325-354.
5. Tan SY, Pepys MB, Hawkins PN. Treatment of amyloidosis. Am J Kidney Dis. 26:1995;267-285.
6. of outstanding interest Kelly JW. Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol. 6:1996;11-17 This review summarizes publications prior to 1996 which support the hypothesis that conformational changes in amyloidogenic proteins lead to amyloid fibril formation.
7. Kelly JW, Lansbury PTJ. A chemical approach to elucidate the mechanism of transthyretin and β-protein amyloid fibril formation. Amyloid-Int J Exp Clin Invest. 1:1994;186-205.
8. of special interest Kelly JW. The environmental dependency of protein folding best explains prion and amyloid diseases [Commentary]. Proc Natl Acad Sci USA. 1998; The similarities and differences between prion and amyloid diseases are discussed.
9. Selkoe DJ. Deciphering Alzheimer's disease: the amyloid precursor protein yields new clues. Science. 248:1990;492-495.
10. Selkoe DJ. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol. 10:1994;373-403.
11. Selkoe DJ. Missense on the membrane. Nature. 375:1995;734-735.
12. Selkoe DJ. Amyloid β-protein and the genetics of Alzheimer's disease. J Biol Chem. 271:1996;18295-18298.
13. Selkoe DJ. Alzheimer's disease: genotypes, phenotype and treatments. Science. 275:1997;630-631.
14. of special interest Kelly JW. Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Structure. 5:1997;595-600 This mini-review outlines the progress and challenges regarding the structural characterization of amyloid proteins.
15. Lansbury PT. In pursuit of the molecular structure of the amyloid plaque: new technology provides unexpected and critical information. Biochemistry. 31:1992;6865-6870.
16. of outstanding interest Blake C, Serpell L. Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous beta-sheet helix. Structure. 4:1996;989-998 This paper outlines the structural evidence in favor of the β-helical structural model of transthyretin amyloid.
17. Blake CCF, Serpell LC, Sunde M, Sandgren O, Lundgren E. A molecular model of the amyloid fibril. Bock GR, Goode JA. The Nature and Origin Of Amyloid Fibrils. 1996;6-21 John Wiley and Sons, Chichester.
18. Serpell LC, Sunde M, Fraser PE, Luther PK, Morris EP, Sangren O, Lundgren E, Blake CCF. Examination of the structure of the transthyretin amyloid fibril by image reconstruction from electron micrographs. J Mol Biol. 254:1995;113-118.
19. Lai Z, Lashuel HA, Kelly JW. Characterization of the transthyretin acid denaturation pathway by analytical ultracentrifugation: implications for amyloid fibril formation. Biochemistry. 1998;. in press.
20. of outstanding interest Lai Z, Colon W, Kelly JW. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate which can self-assemble into amyloid. Biochemistry. 35:1996;6470-6482 The authors outline the biophysical methods used to study the competitive denaturation and fibril formation processes exhibited by TTR under acidic conditions.
21. Snyder SW, Ladror US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, Huffaker HJ, Krafft GA, Holzman TF. Amyloid-β aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J. 67:1994;1216-1228.
22. of outstanding interest Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable A-β amyloid protofibrils by atomic force microscopy. Chem Biol. 4:1997;119-125 The time-dependent observation of different quaternary structural intermediates detected by atomic force microscopy during A-β fibril formation is presented.
23. Lomakin A, Chung DS, Benedek GB, Kirschner DA, Teplow DB. On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantification of rate constants. Proc Natl Acad Sci USA. 93:1996;1125-1129.
24. Glenner GG, Ein D, Eanes ED, Bladen HA, Terry W, Page DL. Creation of amyloid fibrils from Bence Jones proteins in vitro. Science. 174:1971;712-714.
25. Shirahama T, Cohen AS. Intralysosomal formation of amyloid fibrils. Am J Pathol. 81:1975;101-116.
26. Shirahama T, Miura K, Ju S-T, Kisilevsky R, Gruys E, Cohen AS. Amyloid enhancing factor-loaded macrophages in amyloid fibril formation. Lab Invest. 62:1990;61-68.
27. Colon W, Kelly JW. Transthyretin acid induced denaturation is required for amyloid fibril formation in vitro. Kelly JW, Baldwin TO. Applications of Enzyme Biotechnology. 1991;99-108 Plenum, New York.
28. Colon W, Kelly JW. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry. 31:1992;8654-8660.
29. Colon W, Lai Z, Lashuel H, McCulloch J, McCutchen S, Miroy G, Peterson S, Kelly JW. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Wetzel R. Protein Misassembly. 1997;161-181 Academic Press, New York.
30. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai X-D, McKay DM, Tintner R, Frangione B, Younkin SG. Production of the Alzheimer amyloid β-protein by normal proteolytic processing. Science. 258:1992;126-129.
31. Seubert P, Vigo-Pelfry C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schossmacher M, Whaley J, Swindlehurts C, et al. Isolation and quantification of soluble Alzheimer's beta peptide from biological fluids. Nature. 359:1992;325-327.
32. of outstanding interest Hurle MR, Helms LR, Li L, Chan W, Wetzel R. A role for destabilizing amino acid replacements in light chain amyloidosis. Proc Natl Acad Sci USA. 91:1994;5446-5450.
33. Wetzel R. For protein misassembly, its the 'I' decade. Cell. 86:1996;699-702 A recommended review based on the role that intermediates play in protein misassembly.
34. Lansbury PT. The chemistry of the scrapie infection - implications of the ICE 9 metaphor. Chem Biol. 2:1995;1-5.
35. Bessen RA, Kocisko DA, Raymond GJ, Nandan S, Lansbury PT, Caughey B. Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature. 375:1995;698-700.
36. Jarrett J, Lansbury PT. Seeding 'one-dimensional crystallization' of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 73:1993;1055-1058.
37. of outstanding interest Booth DR, Sunde M, Bellotti V, Robinson CV, Hutchinson WL, Fraser PE, Hawkins PN, Dobson CM, Radford SE, Blake CCF, Pepys MB. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature. 385:1997;787-793 This paper outlines data that very nicely supports the conformational change hypothesis of amyloid fibril formation. The conclusions are similar to those drawn from earlier studies on TTR and light chain amyloidosis, with the exception that the amyloidogenic intermediate appears to have a molten globule structure.
38. of outstanding interest Funahashi J, Takano K, Ogasahara K, Yamagata Y, Yutani K. The structure, stability, and folding process of amyloidogenic mutant human lysozyme. J Biochem. 120:1996;1216-1223 The detailed kinetics and thermodynamics are presented as a basis for explaining the amyloidogenicity of a familial lysozyme mutation.
39. Prusiner SB. Molecular biology of prion disease. Science. 252:1991;1515-1522.
40. of outstanding interest Prusiner SB. Prion diseases and the BSE crisis. Science. 278:1997;245-251 An excellent review outlining the likely role of conformational changes in prion diseases.
41. of outstanding interest Huang Z, Prusiner SB, Cohen FE. Structures of prion proteins and conformational models for prion diseases. Curr Top Microbiol Immunol. 207:1996;49-67 See annotation [40].
42. Baldwin MA, Cohen FE, Prusiner SB. Prion protein isoforms, a convergence of biological and structural investigations. J Biol Chem. 270:1995;19197-19200.
43. McCutchen S, Colon W, Kelly JW. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry. 32:1993;12119-12127.
44. McCutchen SL, Lai Z, Miroy G, Kelly JW, Colon W. Comparison of lethal and non-lethal transthyretin variants and their relationship to amyloid disease. Biochemistry. 34:1995;13527-13536.
45. of outstanding interest Miroy GJ, Lai Z, Lashuel H, Peterson SA, Strang C, Kelly JW. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci USA. 93:1996;15051-15056 The results of the research presented in this paper demonstrate the feasibility of inhibiting amyloid fibril formation by employing ligands that bind with high affinity to the non-amyloidogenic conformation of an amyloidogenic protein.
46. Hamilton JA, Steinrauf LK, Braden BC, Liepnieks J, Benson MD, Holmgren G, Sandgren O, Steen L. The X-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30 to Met variant to 1.7-Å resolution. J Biol Chem. 268:1993;2416-2424.
47. Hamilton JA, Steinrauf LK, Liepnieks J, Benson MD, Holmgren G, Sandgren O, Steen L. Alteration in molecular structure which results in disease: the Met-30 variant of human plasma transthyretin. Biochim Biophys Acta. 1139:1992;9-16.
48. Steinrauf LK, Hamilton JA, Braden BC, Murrel JR, Benson MD. X-ray crystal structure of the Ala-109-Thr variant of human transthyretin which produces euthyroid hyperthyroxinemia. J Biol Chem. 268:1993;2425-2430.
49. Terry CJ, Damas AM, Oliviera P, Saraiva MJM, Alves IL, Costa PP, Matias PM, Sakaki Y, Blake CCF. Crystal structure of recombinant Met 30 transthyretin suggests a molecular basis for amyloidogenesis in familiar amyloidotic polyneuropathy (FAP). EMBO J. 12:1993;735-741.
50. Damas AM, Ribeiro S, Lamzin VS, Palha JA, Saraiva MJ. Structure of the Val122IIe variant transthyretin-A cardiomyopathic mutant. Acta Crystallogr D. 52:1996;966-972.
51. of outstanding interest Lai Z, McCulloch J, Kelly JW. GdmHCl-induced denaturation and refolding of transthyretin exhibits A marked hysteresis: equilibria with high kinetic barriers. Biochemistry. 36:1997;10230-10239 The authors demonstrate that FAP-associated mutants denature three orders of magnitude faster than wild-type TTR.
52. Pepys MB, Hawkins PN. Human lysozyme gene mutation causes hereditary systemic amyloidosis. Nature. 362:1993;553-557.
53. of outstanding interest Mihara H, Takahashi Y. Engineering peptides and proteins that undergo alpha to beta transitions. Curr Opin Struct Biol. 7:1997;501-508 This review provides an interesting insight into the structural interconversions exhibited by peptides.
54. Lee JP, Stimson ER, Ghilardi JR, Mantyh PW, Lu YA, Felix AM, Llanoss W, Behbin A, Cummins M, Vancriekinge M, et al. H-1 NMR of A-beta amyloid peptide congeners in water solution-conformational changes correlate with plaque competence. Biochemistry. 34:1995;5191-5200.
55. Sorgehan B, Kosmoski J, Glabe C. Surfactant properties of the Alzheimer's A-beta peptides and the mechanism of amyloid aggregation. J Biol Chem. 269:1994;28551-28554.
56. Stine W, Snyder S, Ladrot U, Wade W, Miller M, Perun T, Holzman T, Krafft G. The nanometer-scale structure of amyloid-β visualized by atomic force microscopy. J Protein Chem. 15:1996;193-203.
57. Shivji AP, Brown F, Davies MC, Jennings KH, Roberts CJ, Tendler SJF, Wilkinson MJ, Williams PM. Scanning tunnelling microscopy studies of beta-amyloid fibril structure and assembly. FEBS Lett. 371:1995;25-28.
58. Goldsbury CS, Cooper GJ, Goldie KN, Muller SA, Saafi EL, Gruijters WT, Misur MP, Engel A, Aebi U, Kistler J. Polymorphic fibrillar assembly of human amylin. J Struct Biol. 119:1997;17-27.
59. of special interest Helms LR, Wetzel R. Specificity of abnormal assembly in immunoglobulin light chain deposition disease and amyloidosis. J Mol Biol. 257:1996;77-86 The authors illustrate how a single mutation can destabilize the immunoglobulin light chain and dictate its assembly morphology.
60. Coelho T. Familial amyloid polyneuropathy: new developments in genetics and treatment. Curr Opin Neurol. 9:1996;355-359.